Phase 2
N=25
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
Autism
Bottom Line
View on ClinicalTrials.gov: NCT01308749 ↗Enrolled (actual)
25
Serious AEs
1.6%
Results posted
Jul 2017
Primary outcome: Primary: Number of Participants Who Could Tolerate Twice Daily Oxytocin — 13; 11 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Oxytocin (Drug); Placebo (Drug)
- Age
- Pediatric · 3+ yrs
- Sex
- All
- Sponsor
- University of North Carolina, Chapel Hill
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Could Tolerate Twice Daily Oxytocin |
11; 11 | — |
| PRIMARY Number of Participants Who Could Tolerate Twice Daily Oxytocin |
11; 11 | — |
| SECONDARY Change in Mean Plasma Oxytocin Level During Period 1 - Double Blind Phase |
-0.69; -0.15 | — |
| SECONDARY Change in Mean Weight |
1.4; 2.4 | — |
| SECONDARY Change in Mean Total Social Social Responsiveness Scale (SRS) T-score |
-5.1; -3.9 | 0.023 sig |
| SECONDARY Change in Mean Autism Diagnostic Observation Schedule (ADOS) Total Score |
-0.36; -0.31 | — |
| SECONDARY Change in Mean Aberrant Behavior Checklist (ABC)-Social Withdrawal Subscale Score Over Both Periods |
-3.7; -2.2 | 0.23 |
| SECONDARY Change in Mean Pervasive Developmental Disorder Behavior Inventory - Screening Version (PDDBI-SV) Total Score Over Both Periods |
-3.6; -3.0 | — |
| SECONDARY Change in Mean Systolic Blood Pressure During Period 1 |
-7.6; 1.5 | — |
| SECONDARY Mean Change in Prolactin Levels Over Period 1 |
-3.6; 1.17 | — |
| SECONDARY Mean Change in Temperature During Period 1 |
-0.7; -0.1 | — |
Summary
The investigators propose to conduct this pilot study to evaluate oxytocin as a supplemental treatment for improving social difficulties in individuals with autism.
Eligibility Criteria
Inclusion Criteria
- Between 3 and 17 years old, inclusive.
- Have a clinical diagnosis of autistic disorder confirmed according to Diagnostic Statistical Manual of Mental Disorders-IV criteria by using the Autism Diagnostic Interview - Revised (ADI-R) and/or the Autism Diagnostic Observation Scale (ADOS, Lord et al., 1989).
Exclusion Criteria
- Changes in allied health therapies, behavioral or educational interventions within the past 2 months of the baseline visit other than those associated with school holidays.
- Changes in psychotropic and alternative medication doses in the last 30 days of the baseline visit.
- Subjects with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to, Rett Syndrome, impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder and uncontrolled hypertension), respiratory, hepatic, or gastrointestinal disease.
- Marked sensory impairment such as deafness or blindness that would interfere with conduct of the study.
- Pregnancy/Nursing because of the unknown effects of oxytocin to unborn babies and/or nursing infants. All females of child-bearing potential will be administered a urine or serum pregnancy test at screening and at any point during the study at physician discretion. Refusal to undergo a pregnancy test will result in exclusion from the study. The investigators will share results of pregnancy test with the subject's legal guardian.
- Refusal to practice contraception if sexually active because the effects of exposure to high concentrations of oxytocin on sperm or newly conceived embryos are unknown. Sexually active men and women should not take part in this study if they and their partners are not both using an effective birth control method (for example, women use birth control pills, an intrauterine device (IUD) or a diaphragm and men use condoms).
- Inability of caretakers to speak English.
- Absence of a consistent caretaker to report on symptoms.
- Subjects who, in the Investigator's opinion, might not be suitable for the study.
Data sourced from ClinicalTrials.gov (NCT01308749). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.